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Abstract
Acridone is a unique naturally occurring alkaloid known to associate with several biological activities. 2,3-dimethoxy-10-methyl-10,
8a-dihydroacridin-9 (8aH)-one (4) and its precursor 2- ((3,4-dimethoxyphenyl)methylamino)benzoic acid (3) were synthesized and
investigated for potential antioxidant and inhibitory activity against acetylcholinestrase. The synthetic pathway involves reaction of
2-(methylamino) benzoic acid (1) with 4-chloro-1,2-dimethoxybenzene (2) in presence of CuO and K2CO3 to give the precursor 3.
Subsequent, cyclcondensation of 3 with Conc. H2SO4 afforded the anticipated acridone 4. Furthermore, the dimethoxyacridone
derivative 4 showed potent antiacetylcholinesterase (ACHE) activity at (100 uM) with IC50 = 9.25 uM that is as potent as the
reference drug rivastigmine. Assessment of total antioxidant activity of compounds 3 & 4 in comparison to known standard
compounds revealed the following order: α-tocopherol > Acridone 4 > trolox > butylated hydroxyl anisole (BHA) > butylated
hydroxyl toluene (BHT) > compound 3. Molecular docking characteristics of 3 & 4 within the active site of AChE (PDB: 1ACJ) co-
crystallized with 9-amino-tetrahydroacridine (Tacrine) have been studied. Interestingly, the results revealed comparable binding
poses to the co-crystallized ligand and demonstrates good correlation of the binding energy (DG) with the observed IC50-values.
This finding suggests that compounds 3 & 4 exhibit good antioxidant effect and inhibition of acetylcholinesterase, which might
provide profitable candidates in management of Alzheimer’s disease.
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Introduction
Acridone alkaloids are biologically active fused heterocyclic
rings. They are characteristic metabolites of plants belonging
to the order Sapindales; more specific to Family Rutaceae. This
Family commonly known as Rue or Citrus family; it is a Fam-
ily of flowering plants with approximately 160 genera and over
2000 species. Several pharmacologically active constituents of
plants belonging to this family have been identified; coumarin,
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furoquinoline, phenylpropanoids and acridone alkaloids which
adds a specialty for this Family [1].
Acridone is unique alkaloid known to associate with several
biological activities [2]. It has carbonyl group at 9th position
and nitrogen at 10th position [3]. It is the oxidized prod-
uct of acridine [4, 5]. Acridone is also known by the name
of 9(10H)-acridinone, acridin-9-one, 9-acridanone, acridine-
9 and 9-azanthracene-10-one [6]. The literature demonstrates
that acridone shows anticancer [7, 8] , antimalarial [9], anti-
inflammatory [10] , antiviral [11] and antibacterial activi-
ties [12].
As an extension of our studies on the synthesis of some
new biologically active heterocyclic compounds [13, 14];
©2019 Advanced Research Journals
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this paper reports the synthesis of two new compounds from
a naturally occurring acridone alkaloid with the investiga-
tion of their antioxidant and AChEI activities of novel 2-
((3,4-dimethoxyphenyl)methylamino)benzoic acid 3 and 2,3-
dimethoxy-10-methyl-10,8a-dihydroacridin-9(8aH)-one 4. As
we know that acetylcholinesterase increases the amyloid pro-
tein fibrils formation which is toxic and linked to alzheimer’s
disease [15, 16]. Much physiology of acetylcholinesterase en-
zyme is not so far elucidated very well, so this is an interesting
research area [17].
Latterly, in view of the efficiency of triazole derivatives in
the inhibition of AChE [18], We reported the synthesis and in
vitro evaluation of acridone linked to 1,2,3-triazoles [19]. Fi-
nally, molecular docking of the synthesized compounds to the
active site of acetylcholinestrase will be also undertaken to de-
lineate the underlying mechanism of the observed biological ac-
tivity
Experimental
Chemistry
Melting points, infrared (IR), 1H-, 13C-NMR and Mass spec-
tra were determined using Gallenkamp melting point appara-
tus, Shimadzu MR 470 infrared spectrophotometer, Varian EM
360 (1H-NMR at 240MHz) & (13C-NMR at 75MHz) and HP
Model MS-5988, respectively. Elemental analytical data (C, H,
N) were determined at the Microanalytical Center, Cairo Uni-
versity, Egypt.
2-(methylamino) benzoic acid, 4-chloro-1,2-dimethoxybenzene,
CuO, K2CO3, α- tocopherol, (BHT), (BHA) and trolox were
purchased from Sigma, USA. Ferrozine: a particular ferroin that
is used for detection of iron. Acetylcholinesterase (AChE, E.C.
3.1.1.7, Type V-S Sigma-Aldrich). Potassium dihydrogen phos-
phate, dipotassium hydrogen phosphate, potassium hydroxide,
and sodium hydrogen carbonate were purchased from Fluka.
Synthesis of
2-((3,4-dimethoxyphenyl)methylamino)benzoic acid
(3)
To a solution of 2-(methylamino)-benzoic acid (9.66 g, 0.06
mol) and 4-chloro-1,2-dimethoxy-benzene (8.31 g, 0.06 mol) in
mixture of anhydrous potassium carbonate and 3 g of copper
oxide in 75 ml ethanol was prepared in a 250 ml round-bottomed
flask fitted with an air-condenser. The mixture was boiled un-
der reflux for 4-5 h. The mixture tended to foam during the
earlier part of the heating owing to the evolution of carbon diox-
ide, and hence the large flask is used. When the heating was
completed, the flask was fitted with a steam-distillation head
and the crude product was steam-distilled until all the excess
aniline has been removed. The residual solution contained the
potassium N-phenylanthranilate. Two grams of animal char-
coal was added to this solution and boiled for ~ 5 min, then
filtered while hot. Diluted hydrochloric acid (1:1 v/v) was
added to the filtrate until no further precipitation observed,
and then the mixture was cooled in ice water with stirring. 2-
((3,4-dimethoxyphenyl)methylamino)benzoic acid was filtered
under reduced pressure, washed with water, drain and dried.
The acid was recrystallized from aqueous ethanol with addi-
tion of charcoal [20]. Yield: 14.1 g(83%); m.p. 133-135◦C;
IR (KBr, cm−1) : 3429 cm−1 (OH), 2989 cm−1 (CH-arom.),
2850 cm−1 (CH-aliph.), 1737(C=O). 1H-NMR (DMSO-d6) 3.5
[s, 6H, OCH3], 2.5 (s, 3H, N-CH3), 7.0–8.0 [m, 7H, Ar–H],
10.9 [s, 1H, COOH].13C-NMR(75MHz, CD3OD):148.2(C-1),
138.3(C-2), 116.3(C-3), 123.8(C-4), 142.3(C-5), 103.4(C-6),
40.2(C-7), 144.5(C-8), 113.1(C-9), 130.6(C-10), 118.4(C-11),
134.8(C-12), 120.4(C-13), 161.4(C-14), 56.6(C-15), 56.2(C-
16). MS (m/z): 287 (M+, 70.15%), 256 (5.00%), 225 (14.29%),
143 (81.00%), 114 (5.00%), 97 (100%). Elemental analysis,
calc. for C16H17NO4 (287); calc.(found): C: 66.89(66.15); H:
5.9(5.30); N: 4.80(5.20).
Synthesis of
2,3-dimethoxy-10-methyl-10,8a-dihydroacridin-9(8aH)-one
(4 )
A mixture of 5.74 g (0.02 M) of 2-((3,4-dimethoxyphenyl)
methyl amino)benzoic acid (3) and 10 ml of conc. sulfuric acid
was prepared in a conical flask and heated for 4 h on a steam
bath. The hot dark green solution was poured slowly and cau-
tiously into 200 ml of boiling water in a 500 ml beaker, allowed
the acid to run down the side of the beaker to avoid “spattering”.
The mixture was boiled for 5 min, and it was filtered while hot
through a Buchner funnel. The precipitate was washed with hot
water. For purification, acridone was transferred to a solution of
4 g of hydrated sodium carbonate in 50 ml of water, boiled for
5 min, and then filtered while hot. Acridone was washed with
boiling water and dried thoroughly. Recrystallization from acetic
acid using charcoal or better sublimation, gives the bright yellow
product. Yield 10.18 g (70%); m.p. 310-312◦C. IR (KBr, cm−1):
3041 and 2927 cm−1 (CH-arom.), 2854 cm−1 (CH-aliph.),
1542 (C=O), 1504 (-CH2- def.),1256, 1130 (C-CO-C, diaryl ke-
tone), 1095 (C-O), 879 (1,2,4-trisubstituted benzene),. 1H-NMR
(DMSO-d6): 2.3 (s, 3H, N-CH3), 2.9 [s, 6H, OCH3], 7.2–7.7 [m,
6H, Ar–H]. 13CNMR(75MHz, CD3OD): 118.4(C-1), 112.2(C-
1′), 138.3(C-2), 147.7(C-2′), 148.2(C-3), 98.6(C-4), 129.7 (C-
5), 49.9 (C-5′), 123.8(C-6), 130.6(C-7), 134.8(C-8), 50.9(C-8′),
190.0(C-9), 36.5(C-10), 56.2(C-11), 59.0(C-12). MS (m/z): 271
(M+, 36%), 238 (51%), 190 (73%), 143 (78%), 104 (86%),
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90 (100%). Elemental analysis, calc. for C16H12NO3 (271);
calc.(found): C: 70.84(71.00); H: 4.42(4.80); N: 5.16(5.20).
Biological testing
Estimation of AChE-Inhibitory Activity, in-vitro
Assessment of IC50 of ACHE inhibitory activity has been carried
out according to Zdrazilova’s modification [21]. Compounds 3
and 4 were dissolved in 10 ml of a mixture of DMSO-methanol
(1:1) and diluted with 0.1 M KH2PO4/K2HPO4 buffer (pH =
8.0) to obtain final concentrations of 25, 50 and 100 µM. All
experiments were achieved at 25 ◦C, using three different con-
centrations for each compound and tested in triplicate to attain
a range of 20–80% inhibition of AChE. The modified procedure
involves using a 96-well plate reader (BioTek ELx808, High-
land Park, IL, USA). Each well contain 50 ul potassium phos-
phate buffer (KH2PO4/ K2HPO4, 0.1 M, pH= 8), the respec-
tive amount of sample (25, 50 and 100 ul dissolved in DMSO-
methanol mixture, and 25 ul enzyme (final concentration 0.22
U/ml in buffer). They were incubated for 20 min at room tem-
perature, and then, 125 ul of 5,5′-dithio-bis-2-nitrobenzoic acid
(DTNB) (3 mM in buffer) was added. The hydrolysis of ace-
tythiocholine, catalyzed by AChE, after 20 min of addition then
determined by measuring the change in absorbance spectropho-
tometrically at λmax = 405 nm. The IC50 values were deter-
mined graphically from inhibition curves (log inhibitor concen-
tration versus percent of inhibition). A control experiment was
performed under the same conditions without inhibitor and the
blank contained buffer, DMSO, 5,5′-dithio-bis-2-nitrobenzoic
acid (DTNB), and substrate.
Antioxidant properties of synthesized compounds 3
and 4
Evaluation of reducing power
The reducing power of compounds 3 and 4 was measured ac-
cording to the method of Oyaizu [22]. The absorbance was mea-
sured at λmax =700 nm. α- tocopherol, BHA and BHT were
used as standard antioxidants.
Estimation of free radical scavenging activity
The free radical scavenging activity of compounds 3 and 4 was
measured with 1,1-diphenyl-2-picrylhydrazil (DPPH·) using the
modified method of Takashira and Ohtake [23] . The percent
inhibition activity was calculated using the following equation:
(%) Inhibition = [(A0 – A1)/A0 x 100]
Where A0 is the absorbance of the control reaction and A1 is
the absorbance in the presence of compounds 3 and 4 samples.
Evaluation of total antioxidant activity
The total antioxidant activity was evaluated according to the
thiocyanate method of Osawa and Namiki [24] with slight mod-
ifications. α- tocopherol, trolox, BHA and BHT were used as
standard antioxidants.
The % inhibition of lipid peroxidation was calculated accord-
ing to the following equation:
% Inhibition = [(A0 – A1)/A0 x 100]
Where A0 is the absorbance of the control reaction and A1 is
the absorbance in the presence of compounds 3 and 4 or stan-
dards.
Detection of chelating activity on Fe2+
The chelating activity of compounds 3 and 4 with ferrous ions
(Fe2+) was detected according to the method of Decker and
Welch [25]. The absorbance was measured spectrophotometri-
cally at λmax = 562 nm. A lower absorbance indicates a higher
chelating power. The chelating activity of compounds 3 and 4
were compared with that of EDTA at a level of 0.037 mg/ml.
% Chelating activity was calculated using the following for-
mula:
[1 – (Absorbance of sample / Absorbance of control)] x 100]
Control test was performed without addition of compounds 3
and 4
Molecular docking
Docking simulation study has been performed in the CADD Lab.
(Dept. of pharmaceutical Chemistry; Faculty of Pharmacy; Oct.
6 University) using Molecular Operating Environment (MOE
®
)
version 2014.09, Chemical Computing Group Inc., Montreal,
Canada. The computational software operated under “Windows
XP” installed on an Intel Pentium IV PC with a 1.6 GHz proces-
sor and 512 MB memory.
Target compounds optimization The target compounds were
constructed into a 3D model using the builder interface of the
MOE program. After checking their structures and the formal
charges on atoms by 2D depiction, the following steps were car-
ried out:
• The target compounds were subjected to a conformational
search.
• All conformers were subjected to energy minimization,
all the minimizations were performed with MOE until
a root mean square deviation (RMSD) gradient of 0.01
Kcal/mole and RMS distance of 0.1 Å with MMFF94X
force-field and the partial charges were automatically cal-
culated.
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• The obtained database was then saved as Molecular Data
Base (MDB) file to be used in the docking calculations.
Optimization of the enzymes active site The X-ray crystallo-
graphic structure of acetylcholinesterae (PDB Code: 1ACJ), co-
crystallized with tacrine, was obtained from RCSB-Protein data
bank. The enzyme was prepared for docking studies by:
• Hydrogen atoms were added to the system with their stan-
dard geometry.
• The atoms connection and type were checked for any er-
rors with automatic correction.
• Selection of the receptor and its atoms potential were
fixed.
• MOE Site Finder was used for the active site search in the
enzyme structure using all default items. Dummy atoms
were created from the obtained alpha Spheres.
Docking of the target molecules to Acetylcholinesterase active
site Docking of the conformation database of the target com-
pounds was done using MOE-Dock software. The following
methodology was generally applied:
• The enzyme active site file was loaded and the Dock tool
was initiated. The program specifications were adjusted to:
- Ligand atoms as the docking site.
- Triangle matcher as the placement methodology to be used.
- London dG as Scoring methodology to be used and was
adjusted to its default values.
• The MDB file of the ligand to be docked was loaded and
Dock calculations were run automatically. The obtained
poses were studied and the poses showed best ligand-
enzyme interactions were selected and stored for energy
calculations.
Statistical analysis
All the grouped data were statistically evaluated with SPSS/18
software. Hypothesis testing methods included one way analy-
sis of variance (ANOVA). P values of less than 0.05 were con-
sidered to indicate statistical significance. All the results were
expressed as mean ± SD for three successive measurements.
Results and Discussion
Chemistry
The synthesis pathway for preparation of 2-((3,4-dimethoxyphenyl)
methyl amino) benzoic acid 3 and 2,3- dimethoxy-10-methyl-
10, 8a-dihydroacridin-9 (8aH)-one 4 is illustrated in Scheme
1.
The structures of compounds 3 and 4 were ascertained on ba-
sis of elemental analyses, IR, mass, 1HNMR and 13CNMR spec-
tral data. The IR spectrum of compound 3 showed bands at 3429
cm−1 (OH), 2989 cm−1 (CH-arom.), 2850 cm−1 (CH-aliph.),
1737(C=O). Its MS exhibited molecular ion peak 287 (M+,
70.15%) with base peak at 97 (100%) in addition to other signifi-
cant peaks at 225 (14.29%), 143 (81.00%) and 114 (5.00%). The
1H-NMR spectrum in DMSO-d6 shows signals at δ: 2.5 (s, 3H,
N-CH3), 3.5 [s, 6H, OCH3], 7.0–8.0 [m, 7H, Ar–H], and 10.9 [s,
1H, COOH]. The most characteristic signals in 13C-NMR spec-
trum of compound 3 in deuterated methanol (CD3OD) due to the
methoxy and N-methyl groups appeared at δ = 56.6, 56.2, and
40.2 ppm respectively. Moreover, the spectrum showed the sig-
nals of the aromatic C-atoms at the expected δ-values and that
of the carboxylic (C=O) at 161.4 ppm.
The formation of compound 4 is assumed to proceed via de-
hydration of the two molecules of the acid (3) to intermediate
acid hydride followed by cyclization involving nucleophilic ad-
dition and elimination of water to give the acridone 4, (Scheme
2). The IR spectrum of compound 4 showed bands at 3041 and
2927 cm−1 (CH-arom.), 2854 cm−1 (CH-aliph.), 1542 cm−1
(C=O), 1504.7 cm−1 (-CH2- def.), 1256.7, 1130.7 cm−1 (C-
CO-C, diaryl ketone), 1095.8 cm−1 (C-O), 879.8 cm−1 (1,2,4-
trisubstituted benzene). In MS The molecular ion peak 271 (M+,
36%) with base peak at 90 (100%) and other significant peaks at
238 (51%), 190 (73%), 143 (78%) and 104 (86%) are displayed
in its mass spectrum. 1H-NMR spectrum (DMSO-d6) exhibited
signals at 2.3 (s, 3H, N-CH3), 2.9 [s, 6H, OCH3], 7.2–7.7 [m,
6H, Ar–H]. 13C-NMR spectrum in (CD3OD) exhibited signals
at, 36.5(N-CH3), 56.2(OCH3), 59.0(OCH3), 190.0(C=O) indi-
cating the formation of acridone ring.
Biological activity
AChE-Inhibitory Activity
The IC50 values of compounds 3 and 4 were determined us-
ing the spectrophotometric Ellman’s method [26], which is
a simple, rapid and direct method originally developed to
determine the SH and -S-S- group content in proteins [27].
The method is widely applied for assessment of the activity
of cholinesterase inhibitors. Cholinesterase activity is mea-
sured indirectly by quantifying the concentration of 5-thio-2-
nitrobenzoic acid (TNB) ion formed in the reaction between
5,5′-dithio-bis-2-nitrobenzoic acid (DTNB) and thiocholine.
The latter is produced from hydrolysis of acetylthiocholine (
ACh) by cholinesterase [28].
The IC50 values of the studied compounds 3, 4 and rivastig-
mine (Exelon®), a known ACHEI, as a reference drug are sum-
marized in Table 1. Both compounds exhibited slightly lower
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Scheme 1: Synthetic pathway of the targeted compounds 3 & 4
inhibitory activity than the standard drug. Interestingly, com-
pound 3 showed higher anticholinesterase activity than the cy-
clized rigid analog 4 at the studied concentrations of 25, 50,
and 100 µM, and comparable or slightly higher inhibitory ac-
tivity than rivastigmine at 50 and 100 µM respectively. This
2-(3,4-dimethoxypheny-methylamino) benzoic acid 3 is a flexi-
ble molecule and can attain different conformational orientations
within the active site of the enzyme, that might be considered as
carbamate-like substrate.
Antioxidant activity
The antioxidant potential of the studied 2-(3, 4-(dimethoxyphenyl)-
methylamino) benzoic acid 3 and the cyclized acridone analog
4 were investigated through assessment of antioxidant potential.
Figure (1) shows the results expressed as the absorbance of the
formed Perl’s Prussian blue at λmax = 700 nm, formed by the
effect of compounds 3, 4 in comparison to standard antioxidants
Table 1 The IC50 values of the compounds 3, 4 and rivastigmine
against acetylcholinesterase (AChE).
Compds. # Conc.(µM) AChE inhibition
IC50 (µM)
3 25 33.5±0.08
50 16.7±0.04
100 9.25±0.08
4 25 >100
50 >100
100 >100
Rivastigmine 25 11.55
BHA, BHT and α-tocopherol. The maximum reducing activity
could be attained at ~120 µg/ml. This indicates that compounds
3 and 4 are electron donors and could react with free radicals,
converting them to more stable products and terminate the rad-
ical chain reaction. The reducing power of compound 4 was
pronounced than BHA, BHT and compound 3.
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Scheme 2: Proposed formation of compound 4
Figure 1 Reducing power of compounds 3 and 4, BHA, BHTand
α-tocopherol
1,1-Diphenyl-2-picrylhydrazil (DPPH•) is used as a free radi-
cal to evaluate the antioxidative activity of some naturally occur-
ring compounds [14, 29] . The DPPH· radical scavenging effects
of compounds 3 and 4 compared to trolox, as a synthetic an-
tioxidant are presented in Fig. (2), illustrating appreciable free
radical scavenging activities. The studied compounds 3 and 4
showed maximum radical scavenging activity at 6 mg/ml com-
pared with 0.06 mg/ml for Trolox.
The antioxidant activity of compound 4 (four resonating
structures) is more pronounced than compound 3 (two resonat-
ing structures), (scheme 3), due to the presence of conjugated
double bond system, which makes the electrons more delocal-
ized to the carbonyl group [30]. The antioxidant activity of phe-
nolic compounds may result from the neutralization of free rad-
icals [31, 32]. It is also known that the antioxidant activity of
phenolic compounds is closely associated with their structures,
such as substitutions on the aromatic ring and side chain struc-
ture [33]. The structural requirement considered essential for
effective radical scavenging by the acridone derivative 4 is the
presence of methoxy groups in B ring and conjugation to the
C=O.
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Figure 2 Scavenging activities of different concentrations of
compounds 3 and 4 and trolox against
the1,1-diphenyl-2-picryl-hydrazil (DPPH·) radical.
The total antioxidant potential expressed as the inhibitory ef-
fect on peroxidation of linoleic acid emulsion at 100 mg/l of
compounds 3, 4 and standard antioxidants are shown in Fig. 3. In
this respect compound 4 showed higher antioxidant activity than
trolox, BHA, and BHT. The total antioxidant activity decreased
in the order: α-tocopherol > compound 4 > Trolox > BHA >
compound 3 > BHT.
Figure 3 Total antioxidant activities of compounds 3 and 4,
α-tocopherol, Trolox and BHA, BHT (100 mg/l concentration) on
peroxidation of linoleic acid emulsion
Iron (Fe2+) chelating activity
The chelating effect of compounds 3 and 4 on ferrous ions has
been accomplished and the results are showed in Figures 4a,
b respectively. All samples showed the best chelating effect of
16% and 21% at concentration = 1.5 mg/ml after an incubation
time of 60 min. The results in Fig. 4a, b indicated that a signifi-
cant property of compounds 3 and 4 is their capability of block-
ing the oxidative activity of systems with transition metal ion
(Fe2+/Fe3+) that play an essential role in the formation of reac-
tive oxygen species in Fenton’s reactions.
Molecular docking Study
Molecular docking within the present investigation was carried
out using Molecular Operating Environment (MOE
®
) version
Figure 4 Chelating effect of different concentrations of compound 3
on Fe2+ ions (FeCl2) at different incubation times.
Figure 5 Chelating effects of different concentrations of compound 4
on Fe2+ ions (FeCl2) at different incubation times.
2014.09, to explore the possible ligand-target interactions that
might explain the inhibitory effect of the synthesized compounds
on acetylcholinesterase. The study involves 2,3-dimethoxy-10-
methyl-10,8a-dihydro-acridin -9(8a)-one (4), as bioisosteric
analogue of tacrine, in addition to its precursor, 2-(N-(3,4-
dimethoxyphenyl)-methylamino) benzoic acid (3), as flexible
analogue.
Structural analysis of AChE revealed the active site placed
in a cavity near the bottom of a narrow imbedded halfway into
the protein, with 14 aromatic amino acid residues lining a sub-
stantial portion of its surface [34]. This is named as the ‘active
site gorge’ and, further at the gorge mouth a peripheral anionic
binding site (PAS) was found. All 14 amino acids in the aro-
matic gorge are highly conserved across different species [35].
Among the aromatic amino acids, tryptophan 84 is critical and
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Scheme 3: Proposed mechanism of compound 3 antioxidant activity
its substitution with alanine results in a 3000-fold decrease in re-
activity [36]. The gorge penetrates halfway through the enzyme
and is approximately 20 Å long [37].
The active site of AChE contains: (1) an esteratic site (ES)
comprising the catalytic triad Ser200-His440-Glu327, which is
located at the bottom of the gorge; (2) an oxyanion hole (OAH)
that stabilizes the tetrahedral intermediate binding of the carba-
mate carbonyl group; (3) an acyl binding site (ABS) that binds
the acetyl group of ACh or the alkyl moiety of carbamate in-
hibitors; (4) an anionic substrate binding site (AS) that contains
a small number of negative charges but many aromatic residues,
where the quaternary ammonium pole of ACh and of various
ligands binds through a preferential interaction of quarternary
nitrogens or a partial positive charge generated by electron-
withdrawing moieties.
Acetylcholinesterae inhibitors are diverse including several
natural and synthetic chemical classes. Carbamate inhibitors
would be the most efficient [38, 39], meanwhile, other chemical
classes are recognized and approved as ACHEIs inhibitors
involving: tetrahydro-aminoacridine (THA’) also known as
Tacrine; Donepezil; galantamine etc. that has been widely used
therapeutically for management of neurodegenerative condi-
tions.
Several X-ray crystal structures of acetylcholinesterase are
available online. Only some of them are co-crystallised with the
tricyclic inhibitor, Tacrine [37]. Based on structural relevance of
the studied compounds to Tacrine, the crystal structure of acetyl-
cholinesterase (PDB code: 1ACJ) has been downloaded from
Protein Data Bank (https://www.rcsb.org), prepared and used
in the current molecular docking study. Analysis of the ligand-
enzyme interaction (Fig. 6) revealed that the acridine nucleus is
stacked against the indole of Trp84; the phenyl ring of Phe330
is positioned to make hydrophobic contact with the bound lig-
and, and the amino group displays bifurcated hydrogen bonding
with two members of the catalytic triad, Ser81 and Asp72. The
structural and chemical data, together, show the important role
of aromatic groups as binding sites for ligands, and they pro-
vide complementary evidence assigning Trp84 and Phe330 to
the "anionic" subsite of the active site.
In the present investigation the proposed docking algo-
rithm was initially validated by re-docking of Tacrine, the co-
crystallized ligand, to acetylcholinesterase PDB code: 1CAJ).
Whereby, the ligand removed from the complex and then docked
back into the binding site. Heavy-atom root mean square devi-
ation (RMSD) values between top-ranked poses and the exper-
imental crystal structure ranged from ~ 0.2639 to 0.5883 Å.
Subsequently, docking procedures have been executed for the
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Figure 6 Surface map of Tacrine (green)co-crystallized with
acetylcholinesterase (1ACJ) (a); and the corresponding interaction
diagram (b).
investigated compounds 3 & 4. The study successfully identified
binding poses with comparable docking scores (Table 2), indi-
cating that the compounds could potentially bind to the active
site with analogous strengths.
The results in Table 2, showed that the investigated com-
pounds displaying comparable binding ability to acetyl-
cholinesterase, as evident by the observed docking scores (-7.4
– 7.1 kcal/mol) relative to that of the co-crystallized ligand (-
6.04 kcal/mol). In addition, common interaction modes are also
observable. Generally, the observed AChE-inhibiting behavior
of the studied compounds 3 and 4 can be attributed to facilitated
entrance to the gorge and slightly different fitting of (3) to the
active site of AChE.
The deviation from the catalytic triad binding site can be
explained as a result of the presence of the bulky methoxy
groups as substituents. This is well illustrated in case of the rigid
dimethoxyacridone derivative (Fig. 7), whereby its binding re-
stricted to pi- pi interaction with the aromatic amino acid residue
Phe-330. On the other hand, the flexible analog, dimethoxy-N-
methylbenzamide binds to Ser-81 in the catalytic triad position
through H-bond in addition to the pi- pi interaction with Phe-
330 (Fig. 8). Such dual-binding site inhibitors of AChE , e.g.
donepezil, were described by Kryger and Alonso [38, 40, 41]
showing interaction with both the active and the peripheral sites
and might accounts for long acting or what is known as pseudo-
irreversible ACHE inhibition.
According to our results, compound 3 showed the highest
ACHE inhibitory activity (IC50 = 9.25 uM), However, the ac-
tivity greatly reduced as result of structural rigidification upon
cycliztion to the corresponding acridone.
Figure 7 a) 3D representation of dimthoxyacridone derivative
(green)and the cocrystallized ligand, tacrine(yellow); b) Ligand
interaction diagram of dimethoxyacridone 4.
Figure 8 a) 3D representation of dimthoxybenzamide
derivative(yellow) and the cocrystallizedligand, Tacrine (green); b)
Ligand interaction diagram of 3.
Conclusion
Novel dimethoxyacridone have been designed, synthesized, and
evaluated as an efficient antioxidant and anti-AChE compounds.
2-(N-(3,4-dimethoxyphenyl)-methylamino)benzoic acid (3)
(100 uM) showed the highest inhibitory activity of AChE (IC50
= 9.25 uM) being as potent as reference drug, rivastigmine.
Insertion of dimethoxy moieties at 2, 3 position to acridone
lead to higher potency as anti-AChE agent. Also, the present
study showed that antioxidative activity of compound 4 was
more pronounced than 3 depending on its resonating structures.
More studies are needed to prove their medicinal and biological
importance which may pave the way for possible therapeutic
applications.
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Table 2 Docking Scores &interaction modes of tacrine and the investigated Compounds 3 and 4
Compds. Docking Scores
(-dG:Kcal/mol)
Interaction Distance
(Å)
E(kcal/ mol)
Tacrine -6.0433 H-donner:(-NH2/H2O- 3.12 -1.2
634/Ser81) 3.12 -1.2
H-donner:(-NH2/H2O- 3.96 -0.0
634/Asp72) 4.18 -0.8
pi- pi: (phenyl/Phe330)
H-pi:(tetrahydrophenyl/ Trp84)
Compound 3 -7.3507 H-acceptor: COO-/Ser81 3.18 -0.8
pi- pi: (phenyl/Phe330) 3.74 -0.0
Compound 4 -7.1066 pi- pi: (phenyl/Phe330) 3.92 -0.0
pi- pi: (Pyridone/Phe330) 3.99 -0.0
Department,, Faculty of Applied Medical Sciences, October 6
University, Sixth of October City, 12585, Egypt.
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